The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $117.74

Today's change0.00 0.00%
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $117.74

Today's change0.00 0.00%
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc closed at (U.S.)$117.74.

Shares have lost 2.52% over the last five days, but sit 3.70% below their 52-week high. This security has outperformed the S&P 500 by 57.72% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $117.74
  • High--
  • Low--
  • Bid / Ask(U.S.) $108.01 / (U.S.) $119.96
  • YTD % change+58.47%
  • Volume0
  • Average volume (10-day)1,681,275
  • Average volume (1-month)1,538,790
  • Average volume (3-month)1,742,097
  • 52-week range(U.S.) $59.79 to (U.S.) $122.26
  • Beta0.35
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.21
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-94.84%

Vertex Pharmaceuticals Inc has a net profit margin of -94.84%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue179138118351
Total other revenue--------
Total revenue179138118351
Gross profit169129110338
Total cost of revenue1010913
Total operating expense321283335625
Selling / general / administrative75777475
Research & development191225239250
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)41-376278
Other operating expenses, total4879
Operating income-142-144-216-274
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-167-159-232-340
Income after tax-170-159-232-185
Income tax, total311-156
Net income-170-159-23244
Total adjustments to net income--------
Net income before extra. items-170-159-23244
Minority interest000229
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-170-159-23244
Inc. avail. to common incl. extra. items-170-159-23244
Diluted net income-170-159-23244
Dilution adjustment0000
Diluted weighted average shares236234233236
Diluted EPS excluding extraordinary itemsvalue per share-0.72-0.68-1.000.19
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.61-0.78-0.981.24